Table 1 Characteristics of patients with bmCRPC on AA with or without ALP-Bouncing

Patients [n], (%)

84

50 (60)

34 (40)

-

Age, median [years] (IQR)

69.0 (62.3–76.0)

68.0 (61.0–75.5)

70.5 (66.5–76.0)

0.304

Lnn. Metastases [n] (%)

45 (53.6)

27 (54.0)

18 (52.9)

0.924

Visceral Metastases [n] (%)

17 (20.2)

14 (28.0)

3 (8.8)

0.032

Pre CTX [n] (%)

39 (46.4)

24 (48.0)

15 (44.1)

0.726

Post CTX [n] (%)

45 (53.6)

26 (52.0)

19 (55.9)

0.726

Patients died [n] (%)

53 (63.1)

39 (78.0)

14 (41.2)

-

Antiresorptive therapy [n] (%)

56 (66.7)

32 (64.0)

24 (70.6)

0.530

Zoledronic acid [n] (%)

42 (50.0)

24 (48.0)

18 (52.9)

0.821

Denosumab [n] (%)

14 (16.7)

8 (16.0)

6 (17.6)

Best clinical outcome [n] (%)

CR

1 (1.2)

0 (0)

1 (2.9)

PR

51 (60.7)

22 (44.0)

29 (85.3)

SD

20 (23.8)

16 (32.0)

4 (11.8)

PD

12 (14.3)

12 (24.0)

0 (0)

ECOG (all) [n] (%)

0

12 (14.3)

7 (14.0)

5 (14.7)

0.351

1

53 (63.1)

29 (58.0)

24 (70.6)

2

29 (22.6)

14 (28.0)

5 (14.7)

GS ≥ 8 [n] (%)^a

45 (60.8)

29 (67.4)

16 (51.6)

0.169

PSA red. ≥ 50 % [n] (%)

47 (56.0)

19 (38.0)

28 (82.4)

<0.001

PSA red. ≥ 90 % [n] (%)

22 (26.2)

6 (12.0)

16 (47.1)

<0.001

Median PSA Baseline [ng/ml] (IQR)

174 (55–500)

105 (47–457)

151 (54–477)

0.824

Median LDH Baseline [U/l] (IQR)

287 (223–422)

290 (228–565)

252 (218–327)

0.125

Median ALP Baseline [U/l] (IQR)

155 (102–355)

171 (96–381)

154 (114–273)

0.895

ALP rising at 12 w AA [n] (%)

27 (33.3)

27 (57.4)

0 (0)

-

LDH BL > UNL [n] (%)

58 (71.6)

37 (77.1)

21 (63.6)

0.187

LDH normalization [n] (%)

23 (39.0)

10 (27.0)

13 (59.1)

0.015